Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.

Chamoun K, Milton DR, Ledesma C, Young KH, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Marin D, Molldrem JJ, Olson AL, Oran B, Popat UR, Rondon G, Champlin RE, Gulbis AM, Khouri IF.

Biol Blood Marrow Transplant. 2019 Jul;25(7):1347-1354. doi: 10.1016/j.bbmt.2019.02.022. Epub 2019 Mar 1.

PMID:
30826465
2.

A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2.

Herrmann AC, Im JS, Pareek S, Ruiz-Vasquez W, Lu S, Sergeeva A, Mehrens J, He H, Alatrash G, Sukhumalchandra P, St John L, Clise-Dwyer K, Zha D, Molldrem JJ.

Front Immunol. 2019 Jan 18;9:3153. doi: 10.3389/fimmu.2018.03153. eCollection 2018.

3.

Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes.

Alatrash G, Qiao N, Zhang M, Zope M, Perakis AA, Sukhumalchandra P, Philips AV, Garber HR, Kerros C, St John LS, Khouri MR, Khong H, Clise-Dwyer K, Miller LP, Wolpe S, Overwijk WW, Molldrem JJ, Ma Q, Shpall EJ, Mittendorf EA.

Clin Cancer Res. 2019 Apr 15;25(8):2610-2620. doi: 10.1158/1078-0432.CCR-18-1527. Epub 2019 Jan 15.

PMID:
30647079
4.

Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.

Alatrash G, Kidwell KM, Thall PF, Di Stasi A, Chen J, Zope M, Crain AK, Champlin RE, Popat U, Shpall EJ, Jones RB, Andersson BS.

Bone Marrow Transplant. 2019 Aug;54(8):1245-1253. doi: 10.1038/s41409-018-0405-0. Epub 2018 Dec 10.

PMID:
30532055
5.

Computational modeling and confirmation of leukemia-associated minor histocompatibility antigens.

Lansford JL, Dharmasiri U, Chai S, Hunsucker SA, Bortone DS, Keating JE, Schlup IM, Glish GL, Collins EJ, Alatrash G, Molldrem JJ, Armistead PM, Vincent BG.

Blood Adv. 2018 Aug 28;2(16):2052-2062. doi: 10.1182/bloodadvances.2018022475.

6.

Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation.

Yang TH, St John LS, Garber HR, Kerros C, Ruisaard KE, Clise-Dwyer K, Alatrash G, Ma Q, Molldrem JJ.

J Immunol. 2018 Sep 1;201(5):1389-1399. doi: 10.4049/jimmunol.1800324. Epub 2018 Jul 18.

7.

Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma.

Alatrash G, Perakis AA, Kerros C, Peters HL, Sukhumalchandra P, Zhang M, Jakher H, Zope M, Patenia R, Sergeeva A, Yi S, Young KH, Philips AV, Cernosek AM, Garber HR, Qiao N, Weng J, St John LS, Lu S, Clise-Dwyer K, Mittendorf EA, Ma Q, Molldrem JJ.

Clin Cancer Res. 2018 Jul 15;24(14):3386-3396. doi: 10.1158/1078-0432.CCR-17-2626. Epub 2018 Apr 16.

8.

Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response.

Vreeland TJ, Litton JK, Qiao N, Philips AV, Alatrash G, Hale DF, Jackson DO, Peace KM, Greene JM, Berry JS, Clifton GT, Peoples GE, Mittendorf EA.

Clin Immunol. 2018 Jul;192:6-13. doi: 10.1016/j.clim.2018.03.010. Epub 2018 Mar 21.

9.

Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma.

Chahoud J, Sui D, Erwin WD, Gulbis AM, Korbling M, Zhang M, Ahmed S, Alatrash G, Anderlini P, Ciurea SO, Oran B, Fayad LE, Bassett RL Jr, Jabbour EJ, Medeiros LJ, Macapinlac HA, Young KH, Khouri IF.

Clin Cancer Res. 2018 May 15;24(10):2304-2311. doi: 10.1158/1078-0432.CCR-17-3561. Epub 2018 Feb 23.

10.

Targeting PR1 in myeloid leukemia.

Alatrash G, Molldrem JJ, Qazilbash MH.

Oncotarget. 2017 Dec 18;9(4):4280-4281. doi: 10.18632/oncotarget.23403. eCollection 2018 Jan 12. No abstract available.

11.

Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target.

Khan M, Carmona S, Sukhumalchandra P, Roszik J, Philips A, Perakis AA, Kerros C, Zhang M, Qiao N, John LSS, Zope M, Goldberg J, Qazilbash M, Jakher H, Clise-Dwyer K, Qiu Y, Mittendorf EA, Molldrem JJ, Kornblau SM, Alatrash G.

Front Immunol. 2018 Jan 25;8:1975. doi: 10.3389/fimmu.2017.01975. eCollection 2017.

12.

Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.

Gall VA, Philips AV, Qiao N, Clise-Dwyer K, Perakis AA, Zhang M, Clifton GT, Sukhumalchandra P, Ma Q, Reddy SM, Yu D, Molldrem JJ, Peoples GE, Alatrash G, Mittendorf EA.

Cancer Res. 2017 Oct 1;77(19):5374-5383. doi: 10.1158/0008-5472.CAN-16-2774. Epub 2017 Aug 17.

13.

Neuropilin-1 mediates neutrophil elastase uptake and cross-presentation in breast cancer cells.

Kerros C, Tripathi SC, Zha D, Mehrens JM, Sergeeva A, Philips AV, Qiao N, Peters HL, Katayama H, Sukhumalchandra P, Ruisaard KE, Perakis AA, St John LS, Lu S, Mittendorf EA, Clise-Dwyer K, Herrmann AC, Alatrash G, Toniatti C, Hanash SM, Ma Q, Molldrem JJ.

J Biol Chem. 2017 Jun 16;292(24):10295-10305. doi: 10.1074/jbc.M116.773051. Epub 2017 May 3.

14.

Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients.

Clifton GT, Litton JK, Arrington K, Ponniah S, Ibrahim NK, Gall V, Alatrash G, Peoples GE, Mittendorf EA.

Ann Surg Oncol. 2017 Aug;24(8):2161-2167. doi: 10.1245/s10434-017-5844-0. Epub 2017 Mar 17.

15.

Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells.

Peters HL, Tripathi SC, Kerros C, Katayama H, Garber HR, St John LS, Federico L, Meraz IM, Roth JA, Sepesi B, Majidi M, Ruisaard K, Clise-Dwyer K, Roszik J, Gibbons DL, Heymach JV, Swisher SG, Bernatchez C, Alatrash G, Hanash S, Molldrem JJ.

Cancer Immunol Res. 2017 Apr;5(4):319-329. doi: 10.1158/2326-6066.CIR-16-0141. Epub 2017 Mar 2.

16.

Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.

Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SO.

Cancer. 2016 Nov 15;122(21):3316-3326. doi: 10.1002/cncr.30180. Epub 2016 Jul 12.

17.

PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.

Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, Kanodia S, Ruisaard KE, Giralt SA, Estey EH, Cortes J, Komanduri KV, Clise-Dwyer K, Alatrash G, Ma Q, Champlin RE, Molldrem JJ.

Leukemia. 2017 Mar;31(3):697-704. doi: 10.1038/leu.2016.254. Epub 2016 Sep 22.

18.

Targeting Immune Checkpoints in Hematologic Malignancies.

Alatrash G, Daver N, Mittendorf EA.

Pharmacol Rev. 2016 Oct;68(4):1014-1025. Review.

PMID:
27664133
19.

Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL.

Khouri IF, Sui D, Jabbour EJ, Samuels BI, Turturro F, Alatrash G, Anderlini P, Ahmed S, Oran B, Ciurea SO, Marin D, Olson A, Patel KK, Popat UR, Ledesma C, Kadia TM, Ferrajoli A, Burger JA, Jorgensen JL, Medeiros LJ, Bassett RL, Gulbis AM.

Bone Marrow Transplant. 2017 Jan;52(1):28-33. doi: 10.1038/bmt.2016.204. Epub 2016 Sep 5.

20.

Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target.

Alatrash G, Garber HR, Zhang M, Sukhumalchandra P, Qiu Y, Jakher H, Perakis AA, Becker L, Yoo SY, Dwyer KC, Coombes K, Talukder AH, John LSS, Senyukov V, Lee DA, Sergeeva A, He H, Ma Q, Armistead PM, Roszik J, Mittendorf EA, Molldrem JJ, Hawke D, Lizee G, Kornblau SM.

Leukemia. 2017 Jan;31(1):234-237. doi: 10.1038/leu.2016.249. Epub 2016 Aug 30. No abstract available.

21.

PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia.

St John LS, Wan L, He H, Garber HR, Clise-Dwyer K, Alatrash G, Rezvani K, Shpall EJ, Bollard CM, Ma Q, Molldrem JJ.

Cytotherapy. 2016 Aug;18(8):995-1001. doi: 10.1016/j.jcyt.2016.05.007.

22.

Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.

Alatrash G, Thall PF, Valdez BC, Fox PS, Ning J, Garber HR, Janbey S, Worth LL, Popat U, Hosing C, Alousi AM, Kebriaei P, Shpall EJ, Jones RB, de Lima M, Rondon G, Chen J, Champlin RE, Andersson BS.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1792-1800. doi: 10.1016/j.bbmt.2016.06.023. Epub 2016 Jul 1.

23.

A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.

Ma Q, Garber HR, Lu S, He H, Tallis E, Ding X, Sergeeva A, Wood MS, Dotti G, Salvado B, Ruisaard K, Clise-Dwyer K, John LS, Rezvani K, Alatrash G, Shpall EJ, Molldrem JJ.

Cytotherapy. 2016 Aug;18(8):985-994. doi: 10.1016/j.jcyt.2016.05.001. Epub 2016 Jun 2.

24.

Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells.

Chawla A, Alatrash G, Philips AV, Qiao N, Sukhumalchandra P, Kerros C, Diaconu I, Gall V, Neal S, Peters HL, Clise-Dwyer K, Molldrem JJ, Mittendorf EA.

Cancer Immunol Immunother. 2016 Jun;65(6):741-51. doi: 10.1007/s00262-016-1841-6. Epub 2016 Apr 29.

25.

Activity of 8F4, a T-cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo.

Sergeeva A, He H, Ruisaard K, St John L, Alatrash G, Clise-Dwyer K, Li D, Patenia R, Hong R, Sukhumalchandra P, You MJ, Gagea M, Ma Q, Molldrem JJ.

Leukemia. 2016 Jul;30(7):1475-84. doi: 10.1038/leu.2016.57. Epub 2016 Mar 8.

26.

Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Lee HC, Saliba RM, Rondon G, Chen J, Charafeddine Y, Medeiros LJ, Alatrash G, Andersson BS, Popat U, Kebriaei P, Ciurea S, Oran B, Shpall E, Champlin R.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1948-54. doi: 10.1016/j.bbmt.2015.07.005. Epub 2015 Jul 14.

27.

Peptide/MHC tetramer-based sorting of CD8⁺ T cells to a leukemia antigen yields clonotypes drawn nonspecifically from an underlying restricted repertoire.

Hunsucker SA, McGary CS, Vincent BG, Enyenihi AA, Waugh JP, McKinnon KP, Bixby LM, Ropp PA, Coghill JM, Wood WA, Gabriel DA, Sarantopoulos S, Shea TC, Serody JS, Alatrash G, Rodriguez-Cruz T, Lizée G, Buntzman AS, Frelinger JA, Glish GL, Armistead PM.

Cancer Immunol Res. 2015 Mar;3(3):228-35. doi: 10.1158/2326-6066.CIR-14-0001. Epub 2015 Jan 9.

28.

Immune checkpoints: A therapeutic target in triple negative breast cancer.

Chawla A, Philips AV, Alatrash G, Mittendorf E.

Oncoimmunology. 2014 Jan 1;3(3):e28325. Epub 2014 Apr 8.

29.

PD-L1 expression in triple-negative breast cancer.

Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G.

Cancer Immunol Res. 2014 Apr;2(4):361-70. doi: 10.1158/2326-6066.CIR-13-0127. Epub 2014 Jan 10.

30.

Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival time.

Tang X, Alatrash G, Ning J, Jakher H, Stafford P, Zope M, Shpall EJ, Jones RB, Champlin RE, Thall PF, Andersson BS.

Biol Blood Marrow Transplant. 2014 Aug;20(8):1139-44. doi: 10.1016/j.bbmt.2014.04.003. Epub 2014 Apr 13.

31.

Immune aspects of the breast tumor microenvironment.

Chawla A, Alatrash G, Wu Y, Mittendorf EA.

Breast Cancer Manag. 2013 May 1;2(3):231-244.

32.

Adoptive T-cell therapy for Leukemia.

Garber HR, Mirza A, Mittendorf EA, Alatrash G.

Mol Cell Ther. 2014 Aug 12;2:25. doi: 10.1186/2052-8426-2-25. eCollection 2014. Review.

33.

Targeting cathepsin G in myeloid leukemia.

Alatrash G.

Oncoimmunology. 2013 Apr 1;2(4):e23442.

34.

Cancer immunotherapies, their safety and toxicity.

Alatrash G, Jakher H, Stafford PD, Mittendorf EA.

Expert Opin Drug Saf. 2013 Sep;12(5):631-45. doi: 10.1517/14740338.2013.795944. Epub 2013 May 14. Review.

PMID:
23668362
35.

A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia.

Zhang M, Sukhumalchandra P, Enyenihi AA, St John LS, Hunsucker SA, Mittendorf EA, Sergeeva A, Ruisaard K, Al-Atrache Z, Ropp PA, Jakher H, Rodriguez-Cruz T, Lizee G, Clise-Dwyer K, Lu S, Molldrem JJ, Glish GL, Armistead PM, Alatrash G.

Clin Cancer Res. 2013 Jan 1;19(1):247-57. doi: 10.1158/1078-0432.CCR-12-2753. Epub 2012 Nov 12.

36.

Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy.

Alatrash G, Mittendorf EA, Sergeeva A, Sukhumalchandra P, Qiao N, Zhang M, St John LS, Ruisaard K, Haugen CE, Al-Atrache Z, Jakher H, Philips AV, Ding X, Chen JQ, Wu Y, Patenia RS, Bernatchez C, Vence LM, Radvanyi LG, Hwu P, Clise-Dwyer K, Ma Q, Lu S, Molldrem JJ.

J Immunol. 2012 Dec 1;189(11):5476-84. doi: 10.4049/jimmunol.1201221. Epub 2012 Oct 26.

37.

Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.

Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE.

Biol Blood Marrow Transplant. 2012 Dec;18(12):1835-44. doi: 10.1016/j.bbmt.2012.07.003. Epub 2012 Jul 11.

38.

Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anticancer adaptive immune response.

Mittendorf EA, Alatrash G, Qiao N, Wu Y, Sukhumalchandra P, St John LS, Philips AV, Xiao H, Zhang M, Ruisaard K, Clise-Dwyer K, Lu S, Molldrem JJ.

Cancer Res. 2012 Jul 1;72(13):3153-62. doi: 10.1158/0008-5472.CAN-11-4135. Epub 2012 May 7.

39.

The role of antigen cross-presentation from leukemia blasts on immunity to the leukemia-associated antigen PR1.

Alatrash G, Ono Y, Sergeeva A, Sukhumalchandra P, Zhang M, St John LS, Yang TH, Ruisaard K, Armistead PM, Mittendorf EA, He H, Qiao N, Rodriguez-Cruz T, Liang S, Clise-Dwyer K, Wieder ED, Lizee G, Lu S, Molldrem JJ.

J Immunother. 2012 May;35(4):309-20. doi: 10.1097/CJI.0b013e31824b3b14.

40.

Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data.

Armistead PM, Liang S, Li H, Lu S, Van Bergen CA, Alatrash G, St John L, Hunsucker SA, Sarantopoulos S, Falkenburg JH, Molldrem JJ.

PLoS One. 2011;6(8):e23217. doi: 10.1371/journal.pone.0023217. Epub 2011 Aug 9.

41.

Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes.

Weng J, Cha SC, Matsueda S, Alatrash G, Popescu MS, Yi Q, Molldrem JJ, Wang M, Neelapu SS, Kwak LW.

Clin Cancer Res. 2011 Sep 15;17(18):5945-52. doi: 10.1158/1078-0432.CCR-11-0970. Epub 2011 Aug 3.

42.

Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials.

Mittendorf EA, Alatrash G, Xiao H, Clifton GT, Murray JL, Peoples GE.

Expert Rev Vaccines. 2011 Jun;10(6):755-74. doi: 10.1586/erv.11.59. Review.

PMID:
21692698
43.

Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome.

Alatrash G, Pelosini M, Saliba RM, Koca E, Rondon G, Andersson BS, Chiattone A, Zhang W, Giralt SA, Cernosek AM, Kebriaei P, Alousi AM, Popat UR, Hosing C, Khouri IF, Champlin RE, de Lima MJ.

Biol Blood Marrow Transplant. 2011 Dec;17(12):1841-5. doi: 10.1016/j.bbmt.2011.05.018. Epub 2011 May 27.

44.

Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.

Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, Xiao L, Kerbauy F, Chiattone A, Rondon G, Qazilbash MH, Giralt SA, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Nieto Y, Saliba RM, Champlin RE, Andersson BS.

Biol Blood Marrow Transplant. 2011 Oct;17(10):1490-6. doi: 10.1016/j.bbmt.2011.02.007. Epub 2011 Feb 18.

45.

Vaccines as consolidation therapy for myeloid leukemia.

Alatrash G, Molldrem JJ.

Expert Rev Hematol. 2011 Feb;4(1):37-50. doi: 10.1586/ehm.10.80. Review.

46.

An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells.

Sergeeva A, Alatrash G, He H, Ruisaard K, Lu S, Wygant J, McIntyre BW, Ma Q, Li D, St John L, Clise-Dwyer K, Molldrem JJ.

Blood. 2011 Apr 21;117(16):4262-72. doi: 10.1182/blood-2010-07-299248. Epub 2011 Feb 4.

47.

Immune rage against MAGE unleashed.

Molldrem JJ, Alatrash G.

Blood. 2010 Sep 16;116(11):1824-5. doi: 10.1182/blood-2010-06-292912. No abstract available.

48.

Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model.

Ma Q, Wang C, Jones D, Quintanilla KE, Li D, Wang Y, Wieder ED, Clise-Dwyer K, Alatrash G, Mj Y, Munsell MF, Lu S, Qazilbash MH, Molldrem JJ.

Cytotherapy. 2010 Dec;12(8):1056-62. doi: 10.3109/14653249.2010.506506. Epub 2010 Aug 24.

49.

PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal.

Kanodia S, Wieder E, Lu S, Talpaz M, Alatrash G, Clise-Dwyer K, Molldrem JJ.

PLoS One. 2010 Jul 26;5(7):e11770. doi: 10.1371/journal.pone.0011770.

50.

Cyclic neutropenia associated with T cell immunity to granulocyte proteases and a double de novo mutation in GFI1, a transcriptional regulator of ELANE.

Armistead PM, Wieder E, Akande O, Alatrash G, Quintanilla K, Liang S, Molldrem J.

Br J Haematol. 2010 Sep;150(6):716-9. doi: 10.1111/j.1365-2141.2010.08274.x. No abstract available.

Supplemental Content

Loading ...
Support Center